Insider Selling: Forty Seven Inc (FTSV) Insider Sells 16,500 Shares of Stock

Share on StockTwits

Forty Seven Inc (NASDAQ:FTSV) insider Mark Anthony Mccamish sold 16,500 shares of Forty Seven stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $12.10, for a total transaction of $199,650.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Mark Anthony Mccamish also recently made the following trade(s):

  • On Thursday, April 18th, Mark Anthony Mccamish sold 16,500 shares of Forty Seven stock. The shares were sold at an average price of $18.12, for a total transaction of $298,980.00.
  • On Tuesday, March 19th, Mark Anthony Mccamish sold 16,500 shares of Forty Seven stock. The shares were sold at an average price of $18.15, for a total transaction of $299,475.00.

FTSV traded down $0.08 during trading on Wednesday, reaching $12.46. The company had a trading volume of 231,300 shares, compared to its average volume of 179,249. Forty Seven Inc has a 12 month low of $10.50 and a 12 month high of $23.83. The firm has a market cap of $393.24 million and a P/E ratio of -3.32.

Forty Seven (NASDAQ:FTSV) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.14). As a group, research analysts forecast that Forty Seven Inc will post -2.85 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. TD Asset Management Inc. lifted its stake in Forty Seven by 8.1% in the first quarter. TD Asset Management Inc. now owns 14,637 shares of the company’s stock valued at $237,000 after buying an additional 1,100 shares in the last quarter. Raymond James & Associates lifted its stake in Forty Seven by 4.9% in the first quarter. Raymond James & Associates now owns 41,002 shares of the company’s stock valued at $663,000 after buying an additional 1,929 shares in the last quarter. PNC Financial Services Group Inc. bought a new position in Forty Seven in the first quarter valued at approximately $32,000. Citigroup Inc. lifted its stake in Forty Seven by 173.8% in the first quarter. Citigroup Inc. now owns 4,189 shares of the company’s stock valued at $68,000 after buying an additional 2,659 shares in the last quarter. Finally, BNP Paribas Arbitrage SA bought a new position in Forty Seven in the first quarter valued at approximately $48,000. 43.70% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently issued reports on FTSV. Zacks Investment Research upgraded shares of Forty Seven from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Wednesday, May 8th. HC Wainwright set a $21.00 price objective on shares of Forty Seven and gave the company a “buy” rating in a report on Tuesday, May 14th. Guggenheim began coverage on shares of Forty Seven in a report on Friday, April 12th. They set a “buy” rating for the company. Finally, Oppenheimer restated a “buy” rating on shares of Forty Seven in a report on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Forty Seven has a consensus rating of “Buy” and an average price target of $26.75.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Forty Seven Inc (FTSV) Insider Sells 16,500 Shares of Stock” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4349665/insider-selling-forty-seven-inc-ftsv-insider-sells-16500-shares-of-stock.html.

About Forty Seven

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Recommended Story: What is the NASDAQ Stock Market?

Insider Buying and Selling by Quarter for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

General Mills  Issues FY 2020 Earnings Guidance
General Mills Issues FY 2020 Earnings Guidance
Starwood Property Trust, Inc.  to Issue Quarterly Dividend of $0.48
Starwood Property Trust, Inc. to Issue Quarterly Dividend of $0.48
OHA Investment Corp  Declares Quarterly Dividend of $0.02
OHA Investment Corp Declares Quarterly Dividend of $0.02
Park Hotels & Resorts Inc  to Issue $0.45 Quarterly Dividend
Park Hotels & Resorts Inc to Issue $0.45 Quarterly Dividend
Morses Club PLC  Plans Dividend Increase – GBX 5.20 Per Share
Morses Club PLC Plans Dividend Increase – GBX 5.20 Per Share
$415.89 Million in Sales Expected for Houghton Mifflin Harcourt Co  This Quarter
$415.89 Million in Sales Expected for Houghton Mifflin Harcourt Co This Quarter


© 2006-2019 Ticker Report